Royal Philips Buys BioTelemetry

Royal Philips Buys BioTelemetry

The medical device giant Royal Philips (NYSE: PHG) is back with a new deal, adding BioTelemetry, Inc. (NYSE: BEAT). The deal is valued at $2.8 billion, consisting of $72.00 per share in cash, or a 16.5% premium to BEAT’s closing price on December 17, 2020. BioTelemetry, formerly known as CardioNet, is a leading provider of remote cardiac diagnostics and monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing for healthcare and clinical research customers. BioTelemetry generated an annualized 2020 revenue of $458 million and annualized 2020 EBITDA of $92.3 million. The acquisition is a strong fit with... Read More »
Medical Device Makers Upgrade with Digital Health Deals

Medical Device Makers Upgrade with Digital Health Deals

This week BioTelemetry, Inc. (NASDAQ: BEAT) purchased Geneva Healthcare, Inc. for $45 million, continuing the 2018 trend of medical device companies acquiring digital health groups. BioTelemetry provides cardiac monitoring device manufacturing and monitoring and wanted Geneva’s proprietary cloud-based platform. Its technology aggregates data from device manufacturers’ systems, enabling a company to remotely monitor a patient’s implantable cardiac devices such as pacemakers, defibrillators and loop recorders. Geneva’s platform provides physicians with a single portal to order patient monitoring, view monitoring results and request routine device checks.... Read More »